M-CHIP characteristics
| Variable . | Patients who had NGS before first treatment (cohort A) (n = 92) . | Patients who had NGS after prior treatment (cohort B) (n = 52) . | P value . |
|---|---|---|---|
| Total number of M-CHIP mutations | .21 | ||
| 1 | 77 (84%) | 39 (75%) | |
| ≥2 | 15 (16%) | 13 (25%) | |
| Most common M-CHIP mutations (>10%) | .02 | ||
| DNMT3A | 43 (47%) | 16 (31%) | |
| TET2 | 20 (22%) | 9 (17%) | |
| BRCC3 | 12 (13%) | 1 (2%) | |
| ASXL1 | 9 (10%) | 12 (23%) | |
| M-CHIP VAF category | .78 | ||
| VAF <10% | 50 (54%) | 27 (52%) | |
| VAF ≥10% | 43 (46%) | 25 (48%) | |
| M-CHIP largest clone VAF % (median, IQR) | 8.1% (4.6-19.2) | 9.2% (4.4-17.6) | .53 |
| Variable . | Patients who had NGS before first treatment (cohort A) (n = 92) . | Patients who had NGS after prior treatment (cohort B) (n = 52) . | P value . |
|---|---|---|---|
| Total number of M-CHIP mutations | .21 | ||
| 1 | 77 (84%) | 39 (75%) | |
| ≥2 | 15 (16%) | 13 (25%) | |
| Most common M-CHIP mutations (>10%) | .02 | ||
| DNMT3A | 43 (47%) | 16 (31%) | |
| TET2 | 20 (22%) | 9 (17%) | |
| BRCC3 | 12 (13%) | 1 (2%) | |
| ASXL1 | 9 (10%) | 12 (23%) | |
| M-CHIP VAF category | .78 | ||
| VAF <10% | 50 (54%) | 27 (52%) | |
| VAF ≥10% | 43 (46%) | 25 (48%) | |
| M-CHIP largest clone VAF % (median, IQR) | 8.1% (4.6-19.2) | 9.2% (4.4-17.6) | .53 |
Boldface indicates significant P value of <0.05.
IQR, interquartile range; M-CHIP, myeloid clonal hematopoesis of indeterminate potential; VAF, variant allele frequency.